GlobeNewswire BiotechnologyCodex · 实盘不做把握 2/10
北京时间·🕒 发布 19:00:00时区推断·⟳ 抓取 19:02:23·⚡ 决策 08-04 19:34:59 +32m36s·84.1 天前
Sagimet Biosciences宣布参加Canaccord Genuity年度成长会议
本次仅为公司管理层参加投资者会议和炉边谈话的日程公告，没有披露临床数据、监管进展、融资、合作或商业化增量。
📄 原文GlobeNewswire Biotechnology↗ 原文
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopha…
不做 Sagimet Biosciences（SGMT.US）
常规投资者会议参与公告，没有新增临床、监管、合作、融资或商业化事实，无法形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次仅为公司管理层参加投资者会议和炉边谈话的日程公告，没有披露临床数据、监管进展、融资、合作或商业化增量。
主要风险
- 若会议期间另行披露临床或监管实质进展，应由新信号重新研判。
原文全文
展开原文 · 1,054 字
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。